ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Malignancy"

  • 2022 American Transplant Congress

    Is Repeat Resection for Recurrent Intrahepatic Cholangiocarcinoma Warranted? Outcomes of an International Multicenter Analysis

    M. L. Holzner1, V. Mazzaferro2, M. Droz dit Busset2, L. Aldrighetti3, F. Ratti3, K. Hasegawa4, J. Arita4, G. Sapisochin5, P. Abreu5, W. Schoening6, N. Nevermann6, M. Schmelzle6, J. Pratschke6, S. Florman1, K. Halazun7, M. E. Schwartz1, P. Tabrizian1

    1Recanati/Miller Transplantation Institute, Mount Sinai, New York, NY, 2University of Milan, Milan, Italy, 3San Raffaele Hospital, Milan, Italy, 4University of Tokyo, Tokyo, Japan, 5University of Toronto, Toronto, ON, Canada, 6Charite University, Berlin, Germany, 7Weill Cornell Medical Center, New York, NY

    *Purpose: Recurrence of intrahepatic cholangiocarcinoma (ICC) after liver resection (LR) remains high and optimal therapy for recurrent ICC is challenging. Herein we assess the outcomes…
  • 2022 American Transplant Congress

    De Novo Fibrinogen Alpha Chain Amyloidosis in Kidney Allograft

    T. Khaja1, L. Truong2, G. Nassar1

    1Nephrology, Houston Methodist Hospital, Houston, TX, 2Pathology, Houston Methodist Hospital, Houston, TX

    *Purpose: Amyloidosis is a disorder characterized by tissue deposition of misfolded proteins that can lead to organ damage such as renal failure. There are multiple…
  • 2022 American Transplant Congress

    Transplant Combined with Neoadjuvant Therapy Improves Survival for Patients with Liver-Limited, Locally Advanced Intrahepatic Cholangiocarcinoma: A SEER Database Analysis

    G. G. Panayotova1, M. Javle2, S. Pentakota1, F. Paterno1, A. Amin1, L. Brown1, S. Simonishvili1, Y. Qin1, T. Ayorinde1, G. Prakash1, C. Conrad3, J. V. Guarrera1, K. E. Lunsford1

    1Rutgers New Jersey Medical School, Newark, NJ, 2University of Texas, MD Anderson Cancer Center, Houston, TX, 3St. Elizabeth's Medical Center, Boston, MA

    *Purpose: Preliminary single-center data suggest multimodal therapy may improve outcomes for patients with intrahepatic cholangiocarcinoma (iCCA) undergoing liver transplant (LT), particularly in the setting of…
  • 2022 American Transplant Congress

    Metastatic BK Virus-Associated Urothelial Carcinoma Originating in Renal Allograft

    J. Torrealba1, H. Jones1, A. Bhakta2, L. Jia1, D. Wojciechowski2

    1Pathology, UT Southwestern, Dallas, TX, 2Internal Medicine, UT Southwestern, Dallas, TX

    *Purpose: Cases of urinary tract carcinoma associated with BK virus have been reported in kidney transplant recipients; therefore, we postulate that BK virus may play…
  • 2022 American Transplant Congress

    Seroprevalence of HHV8 Among Donors and Recipients with HIV

    P. H. Nambiar1, T. Liang2, J. D. Motter3, W. Werbel3, S. Mehta4, V. Kirchner5, M. Rana6, S. Florman7, J. Odim8, W. Miley9, N. Labo9, D. Whitby9, A. Massie10, D. Segev3, A. Tobian3, C. Durand2

    1Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 2Medicine, Johns Hopkins University, Baltimore, MD, 3Johns Hopkins University, Baltimore, MD, 4New York University Langone Transplant Institute, New York, NY, 5University of Minnesota, Minneapolis, MN, 6Icahn School of Medicine at Mount Sinai, New York, NY, 7Mount Sinai Medical Center, New York, NY, 8National Institute of Health, Bethesda, MD, 9National Cancer Institute, Frederick, MD, 10Johns Hopkins School of Medicine, Baltimore, MD

    *Purpose: Kaposi sarcoma (KS) can develop post-transplant via recipient HHV8 reactivation or donor-acquired HHV8. In the general US population, HHV8 seroprevalence is low (1-5%), yet…
  • 2022 American Transplant Congress

    Cutaneous Angiosarcoma in Solid Organ Transplant Recipients – Novel Case & Review of the Literature

    S. M. Elzein, R. R. Caplan

    Houston Methodist Hospital, Houston, TX

    *Purpose: Cutaneous angiosarcoma, a rare and extremely aggressive malignant neoplasm, has been described in fewer than twenty-five solid organ transplant recipients to date. Secondary, or…
  • 2021 American Transplant Congress

    Treg Lymphotoxin Engages Lymphotoxin Receptor on Cancer and Endothelial Cells to Promote Cancer Metastatic Migration: Mechanisms for Treg-Cancer Interactions

    W. Piao, R. Oakes, C. Paluskievicz, J. Christopher, J. Bromberg

    U Maryland, Baltimore, MD

    *Purpose: Treg immune suppression which is critical for transplant graft survival may also enhance tumor growth and metastases. Treg lymphotoxin (LTα1β2) may directly engage the…
  • 2021 American Transplant Congress

    Cancer Among Kidney Transplant Recipients More Than 20 Years After Transplantation: PTLD Remains the Most Common Cancer Type Even in the Very Long-Term

    T. Schachtner, J. Fuhrmann, T. Mueller

    Nephrology, University Hospital Zurich, Zurich, Switzerland

    *Purpose: Due to an improved patient and kidney allograft survival, cancer is increasingly recognized as the major cause of death after kidney transplantation. Cancer risk…
  • 2021 American Transplant Congress

    Impact of Donation After Circulatory Death Donor Allografts on Outcomes Following Liver Transplantation for Cholangiocarcinoma

    S. Kumar1, S. Lin2, J. D. Schold2

    1Digestive Disease Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, 2Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH

    *Purpose: Improvements in the management of extra-hepatic cholangiocarcinoma (CCA) resulted in allocation of a standardized model for end-stage liver disease (MELD) exception score for liver…
  • 2021 American Transplant Congress

    Excellent Pathological Response with Gemcitabine-based Protocol in Patient with Hilar Cholangiocarcinoma

    A. Saharia1, R. McMillan1, S. Kodali1, M. Javley2, C. M. Mobley1, M. J. Hobeika1, A. Shetty1, D. W. Victor1, R. McFadden1, M. Abdelrahim1, K. Heyne1, A. O. Gaber1, R. M. Ghobrial1

    1Houston Methodist Hospital, Houston, TX, 2MD Anderson Cancer Center, Houston, TX

    *Purpose: The standard treatment for hilar cholangiocarcinoma is using 5FU along with brachytherapy and external beam radiation. The downside of this regimen is the uncertain…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 20
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences